 action novel antidiabet agent englitazon hyperglycem hyperinsulinem ob/ob mice effect CP englitazon ob/ob mice adipocyt soleu muscl ob/ob mice adipocyt administr englitazon plasma glucos insulin frank hypoglycemia diabet nondiabet lean anim glucose-low effect ob/ob mice reduct hyperinsulinemia cessat drug plasma insulin untreat level plasma glucos day englitazon mg/kg day plasma glucos mM insulin nM nonesterifi fatti acid microm glycerol mM triglycerid g/l cholesterol mM effect singl dose basal insulin-stimul lipogenesi adipocyt ob/ob mice mg/kg englitazon day lipogenesi cell vehicle-tr control treatment ob/ob mice mg/kg defect insulin-stimul glycolysi glucos glycogenesi basal glucos oxid glucos isol soleu muscl englitazon microm transport adipocyt protein englitazon insulinomimet insulin-enhanc action vitro glucose- insulin- triglyceride- cholesterol-low properti anim model non-insulin-depend diabet niddm sulfonylurea littl effect new agent benefici effect reduc risk hypoglycemia patient niddm